. 2021 Oct 12;13(10):3568. doi: 10.3390/nu13103568

Table 1.

Characteristics of the included studies.

Study	Design	Study Location	Sample Size	Surgical Procedure (%)	Follow-Up Period (Mean ± SD/Median (IQR), y)	Population	REF
Sjostrom et al., 2012	Non-RCT	Sweden	2010 surgery	Gastric Bypass: 265 (13.2) Gastric Banding: 376 (18.7) Vertical Banded Gastroplasty: 1360 (68.1)	14.7	Patients aged 37 to 60 years and with BMI of at least 34 for men and at least 38 for women.	[23]
Sjostrom et al., 2012	Non-RCT	Sweden	2037 control	-	14.7		[23]
Aminian et al., 2019	Matched Cohort Study	Florida, Ohio, USA	2287 surgery	Roux-en-Y Gastric Bypass: 1443 (63) Sleeve Gastrectomy: 730 (32) Gastric Banding: 109 (5) Duodenal Switch: 5 (0.2)	3.3 (1.2–6.3)	Patients with age 18–80 years, BMI ≥ 30, and diabetes.	[24]
Aminian et al., 2019	Matched Cohort Study	Florida, Ohio, USA	11,435 control		4.0 (2.1–6.1)	Patients with age 18–80 years, BMI ≥ 30, and diabetes.	[24]
Stenberg et al., 2020	Matched Cohort Study	Sweden	11,863 surgery	Gastric Bypass: 10,692 (90.1) Sleeve Gastrectomy: 1171 (9.9)	5.09 ± 2.53	Patients with morbid obesity and hypertension	[25]
Stenberg et al., 2020	Matched Cohort Study	Sweden	26,199 control	-	5.06 ± 2.55	Patients with morbid obesity and hypertension	[25]
Pirlet et al., 2020	Matched Cohort Study	Quebec, Canada	116 surgery	Gastric Bypass: 3 (2.6) Biliopancreatic diversion with duodenal switch: 44 (38) Sleeve gastrectomy: 67 (58) Duodenal Switch only: 2 (1.7)	8.9 (6.3–14.2)	Patients with history of coronary artery disease (CAD) and obesity	[26]
Pirlet et al., 2020	Matched Cohort Study	Quebec, Canada	116 control	-	8.9 (6.3–14.2)		[26]
Moussa et al., 2020	Matched Cohort Study	UK	3701 surgery	N/A	11.2	Patients with BMI ≥ 35 with exclusion of previous MACE	[27]
Moussa et al., 2020	Matched Cohort Study	UK	3701 control	-	11.2	Patients with BMI ≥ 35 with exclusion of previous MACE	[27]
Hung et al., 2020	Matched Cohort Study	Taiwan	1436 surgery	N/A	7.5	Patients with BMI > 35 with co-morbidities or >40	[28]
Hung et al., 2020	Matched Cohort Study	Taiwan	1436 control	-	7.5	Patients with BMI > 35 with co-morbidities or >40	[28]
Doumouras et al., 2021	Matched Cohort Study	Ontario, Canada	1319 surgery	Gastric Bypass: 1049 (79.5) Sleeve Gastrectomy: 270 (20.5)	4.65 (3.09–6.28)	Patients with BMI > 35 with a comorbidity or BMI ≥ 40	[29]
Doumouras et al., 2021	Matched Cohort Study	Ontario, Canada	1319 control	-	4.38 (2.83–6.09)	Patients with BMI > 35 with a comorbidity or BMI ≥ 40	[29]
Naslund et al., 2021	Matched Cohort Study	Sweden	509 surgery	Roux-en-Y Gastric Bypass: 465 (91) Sleeve Gastrectomy: 44 (9)	4.6 (2.7–7.1)	Patients with severe obesity and history of MI	[30]
Naslund et al., 2021	Matched Cohort Study	Sweden	509 control	-	4.6 (2.7–7.1)	Patients with severe obesity and history of MI	[30]
Batsis et al., 2007	Retrospective Cohort	Olmsted, Minnesota, USA	197 surgery	Roux-en-Y Gastric Bypass: 197 (100)	3.3 ± 2.6	Patients with BMI > 35	[31]
Batsis et al., 2007	Retrospective Cohort	Olmsted, Minnesota, USA	163 control		3.3 ± 2.6	Patients with BMI > 35	[31]
Nguyen et al., 2020	Retrospective Cohort	USA	50,296 surgery	N/A	N/A	Adult patients with class II (BMI 35.0 to 39.9) or class III obesity (BMI > 40)	[32]
Nguyen et al., 2020	Retrospective Cohort	USA	1650,647 control	-	N/A		[32]
Yuan et al., 2021	Retrospective Cohort	Minnesota, USA	308 surgery	Roux-en-Y Gastric Bypass: 308 (100)	4.6 (2.7–7.1)	Patients with class II-III obesity (BMI > 35)	[33]
Yuan et al., 2021	Retrospective Cohort	Minnesota, USA	701 control	-	4.6 (2.7–7.1)	Patients with class II-III obesity (BMI > 35)	[33]